Metastatic HR+/HER2- Breast Cancer Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the metastatic hr+/her2- breast cancer market grown in recent years?
The market size for metastatic HR+/HER2-breast cancer has experienced a swift increase in the past years. It’s estimated to escalate from $9.91 billion in 2024 to $10.92 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.3%. The expansion during the historic period can be credited to various factors such as heightened cognizance about early detection, escalating diagnosis rates, the success of clinical trials, pharmaceutical industry investments, and the increasing preference for combination treatments.
How is the metastatic hr+/her2- breast cancer market size expected to evolve during the forecast period?
The market size for metastatic HR+/HER2-breast cancer is poised for substantial growth in the upcoming years, with a projected value of $15.94 billion by 2029, equating to a compound annual growth rate (CAGR) of 9.9%. Factors fueling this anticipated growth include the surge in the adoption of new therapies, proliferation of immunotherapy use, market extension into emergent countries, and the implementation of patient advocacy and care programs with an emphasis on enhancing life quality. Upcoming prominent market trends encompass next-generation sequencing (NGS), developments in liquid biopsy, exploration of new biomarkers, along with advancements in cell and gene therapy and monoclonal antibodies (mAbs).
Get your metastatic hr+/her2- breast cancer market report here!
Which key drivers are propelling the metastatic hr+/her2- breast cancer market’s growth?
The metastatic HR+/HER2- breast cancer market is set to be boosted by the growing usage of hormone replacement therapy (HRT). Commonly used during menopause or in cases of hormone deficiencies, HRT is a medical intervention designed to supplement or replenish hormones that are in deficit within the body. This rise in HRT is attributable to its superior treatment outcomes, fewer side effects in comparison to traditional therapies, and the progress being made in precision medicine. HRT offers particular support in metastatic HR+/HER2- breast cancer cases, as it helps ameliorate menopause-associated estrogen deficiency symptoms, like hot flashes and vaginal dryness, without diminishing the efficacy of endocrine therapies. This is because it primarily addresses hormone imbalances rather than attacking cancer cells themselves, thereby assuring a higher quality of life for cancer patients. Figures from NHS England dated October 2023 substantiate this point, revealing that during 2022-2023 in England, 11 million HRT items were prescribed, a pronounced 47% jump from 2021-2022. Thus, the mounting use of HRT is providing impetus to the metastatic HR+/HER2- breast cancer market.
What are the market segments in the metastatic hr+/her2- breast cancer industry?
The metastatic HR+/HER2- breast cancer market covered in this report is segmented –
1) By Drugs: Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel, Other Drugs
2) By Treatment: Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal Medication
3) By End-User: Hospitals, Clinics, Other End-User
Subsegments:
1) By Paclitaxel: Generic Paclitaxel, Taxol
2) By Tamoxifen: Generic Tamoxifen, Nolvadex
3) By Vinblastine: Generic Vinblastine, Velban
4) By Raloxifene: Generic Raloxifene, Evista
5) By Docetaxel: Generic Docetaxel, Taxotere
6) By Other Drugs: Letrozole, Anastrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp
Which leading companies are shaping the growth of the metastatic hr+/her2- breast cancer market?
Major companies operating in the metastatic HR+/HER2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics
What are the key trends shaping the future of the metastatic hr+/her2- breast cancer market?
Significant players in the metastatic HR+/HER2- breast cancer market are forging ahead with the development of combination therapy to diversify their available treatments, broaden their market coverage and extend their therapeutic indications. This treatment strategy entails the concurrent use of multiple therapeutic agents—these could be chemotherapy, targeted therapy, hormone therapy, immunotherapy, among others—in order to treat medical conditions more efficiently. The method operates by targeting different paths, boosting the overall response to treatment, and minimizing the chances of conditions like cancer developing resistance to any single treatment modality. For example, Merck & Co., Inc., a pharmaceutical company based in the U.S, announced the launch of the Phase 3 KEYNOTE-756 trial in July 2023. The trial, which studied KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, combined with chemotherapy approved by the FDA, reached its primary goal by notably enhancing the pathological complete response (pCR) rate in patients suffering from high-risk, early-stage ER+/HER2- breast cancer. The KEYNOTE-756 trial, which is the first Phase 3 trial demonstrating a statistically significant improvement in the pCR rate with an immunotherapy plan in the neoadjuvant setting for patient population, tested KEYTRUDA alongside chemotherapy as neoadjuvant therapy. This was followed by adjuvant KEYTRUDA combined with endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21220
Which geographic areas are influencing the growth of the metastatic hr+/her2- breast cancer market?
North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2- breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Kidney Transplant Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report
Chronic Kidney Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report
Pediatric Vaccine Global Market Report 2025
https://thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
